Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 8/20 | 0.40 |
| ▸ | PGR | P06401 | 7/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292426 | 0.85 | NR3C1 (0.57) | NR3C1PGRCYP3A4NR3C2 | |
| SCHEMBL291200 | 0.83 | CYP11B1 (0.44) | NR3C1PGRCYP3A4MAPTMEN1 | |
| SCHEMBL291016 | 0.82 | NR3C1 (0.55) | NR3C1PGRNR3C2 | |
| SCHEMBL1680244 | 0.79 | NR3C1 (0.37) | NR3C1PGRCYP3A4NR3C2 | |
| SCHEMBL448531 | 0.75 | DDAH1 (0.42) | GAAKDM4ELMNAALDH1A1HTT | |
| SCHEMBL5781547 | 0.73 | NR3C1 (0.56) | NR3C1PGRCYP3A4NR3C2 | |
| SCHEMBL292375 | 0.71 | LOXL2 (0.40) | NR3C1PGRMAPTNR3C2 | |
| SCHEMBL10313406 | 0.70 | NR3C1 (0.43) | NR3C1PGRCYP3A4NR3C2 | |
| SCHEMBL1633606 | 0.70 | NR3C1 (0.50) | NR3C1PGRCYP3A4NR3C2 | |
| SCHEMBL1634466 | 0.68 | NR3C1 (0.69) | NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014787-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-01-19 | — | — | US | claimed |
| EP-1513810-A1 | 4-(ARYL OR HETEROARYL) -2-BUTYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-03-16 | — | — | EP | claimed |
| US-20040010148-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | claimed |
| WO-2003104195-A1 | 4-(ARYL OR HETEROARYL) -2-BUTYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | claimed |
| EP-2056799-B1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GLAUCOMA OR PROGRESSION THEREOF | BAUSCH & LOMB (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2203160-B1 | PHARMACOLOGICAL ADJUNCTIVE TREATMENT ASSOCIATED WITH GLAUCOMA FILTRATION SURGERY | BAUSCH & LOMB (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-2190431-B1 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST FOR TREATING OR CONTROLLING ANTERIOR-SEGMENT INFLAMMATION | BAUSCH & LOMB (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2364707-B1 | Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof | BAUSCH & LOMB (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20120316199-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN | SOLTA MEDICAL IRELAND LIMITED (IE) | 2012-12-13 | — | — | US | disclosed |
| US-20120065228-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING OCULAR INFLAMMATORY WITH LOWER RISK OF INCREASED INTRAOCULAR PRESSURE | SOLTA MEDICAL, INC. | 2012-03-15 | — | — | US | disclosed |
| EP-2049112-B1 | TREATING INFECTIONS AND SEQUELAE THEREOF WITH COMBINED DISSOCIATED GLUCOCORTICOID RECEPTOR AGONISTS AND ANTI-INFECTIVE AGENTS | BAUSCH & LOMB (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2397140-A1 | Compositions and methods for treating or preventing glaucoma or progression thereof | BAUSCH & LOMB INCORPORATED (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20080058373-A1 | Compositions and Methods for Treating or Preventing Glaucoma or Progression Thereof | VRX HOLDCO LLC | 2008-03-06 | — | — | US | disclosed |
| WO-2008021729-A2 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | BAUSCH & LOMB INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080031884-A1 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | BAUSCH HEALTH US, LLC | 2008-02-07 | — | — | US | disclosed |
| US-20080033008-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFECTIONS AND SEQUELAE THEREOF | BAUSCH HEALTH COMPANIES INC. (CA) | 2008-02-07 | — | — | US | disclosed |
| US-20080009437-A1 | Pharmaceutical Compositions and Method for Treating Dry Eye | SALIX PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2008005686-A2 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST AND AN IMMUNOSUPPRESSIVE AGENT FOR TREATING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-01-10 | — | — | WO | disclosed |
| US-7074806-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-20060014787-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033008-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFECTIONS AND SEQUELAE THEREOF | NR3C1, GNRHR, GSR | NR3C1 1/4885PGR 39/4885CYP3A4 802/4885 |
| US-20080031884-A1 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | PTGIR, GCGR, NR3C1 | NR3C1 3/4885PGR 207/4885CYP3A4 4773/4885 |
| US-20080009437-A1 | Pharmaceutical Compositions and Method for Treating Dry Eye | NR3C1, GCGR, GPBAR1 | NR3C1 1/4885PGR 45/4885CYP3A4 595/4885 |
| US-20080058373-A1 | Compositions and Methods for Treating or Preventing Glaucoma or Progression Thereof | PTGIR, PTGDR, NR3C1 | NR3C1 3/4885PGR 195/4885CYP3A4 1363/4885 |
| US-20120065228-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING OCULAR INFLAMMATORY WITH LOWER RISK OF INCREASED INTRAOCULAR PRESSURE | PTGIR, NR3C1, PTGDR | NR3C1 2/4885PGR 272/4885CYP3A4 1450/4885 |
| US-20060014787-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, MC2R, NR3C2 | NR3C1 1/4885PGR 77/4885CYP3A4 546/4885 |
| US-20040010148-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 154/4885CYP3A4 493/4885 |
| US-20120316199-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN | PTGIR, MC2R, NR3C1 | NR3C1 3/4885PGR 220/4885CYP3A4 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.